AngioVac Aspiration Therapy Registry

ConditionsIntracardiac Thrombus Intracardiac Mass Intravascular Thrombosis Vegetation; Heart Vegetation; Endocarditis Vegetation on Catheter Thrombus of Right Atrium Thrombus of Right Ventricle Thrombus Inferior Vena Cava Thrombus of Pacemaker Electrode Endocarditis Infective Endocarditis, Bacterial Thrombus of Pulmonary Artery Thrombus on Catheter

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorCharite University, Berlin, Germany

About this trial

As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients that were treated with the AngioVac Aspiration System:

1. Quantify Real-World Safety: Composite adverse event rates across diverse populations and indications 2. Assess Effectiveness: Technical and clinical success rates stratified by indication 3. Identify Predictors: Clinical, procedural, and anatomical factors predicting success versus complications 4. Generate Publishable Cohorts: Sufficient statistical power (approx. 1000 patients across 8 indication cohorts) for:

* Indication-specific outcomes * Multivariable prediction models * Time-to-event analyses (30-day and 12-month mortality) 5. Establish Best Practices: Evidence-based recommendations for patient selection, procedural technique, and follow-up

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years at time of AngioVac procedure

Patient underwent percutaneous AngioVac aspiration (any AngioVac model or version used clinically during study period)

Procedure performed within study period (January 2018 (or site's institutional start date) - June 2026)

Written informed consent OR documented waiver/exemption from ethics authority (per local regulations per GDPR)

Disqualifiers

Insufficient documentation to assess primary safety or effectiveness endpoints (e.g. defined as >20% missing data in core endpoint variables)

Patient objection to retrospective data use (where required by local law; GDPR Article 21 opt-out; honored without study impact)

Non-AngioVac procedures: Patients undergoing thrombus/vegetation removal by surgery or other percutaneous devices only (not AngioVac)

Trial population

All patients who underwent an AngioVac procedure during the specified and mentioned time period.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Retrospective analysis of assigned treatment
Other intervention
Participants are not assigned an intervention as part of the study

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

Safety and technical effectiveness of AngioVac

Evaluation of in-hospital safety and procedural effectiveness of AngioVac in real-world practice across indications.

Time frame

From intervention to the end of 12month

Secondary outcomes

Various secondary endpoints

Indication-stratified outcomes, predictors of technical success and adverse events, procedural resource use, device-related complications, and 30-day / 12-month follow-up where available.

Time frame

From intervention to the end of 12month

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Charite University, Berlin, Germany

Lead sponsor

Angiodynamics, Inc.

Collaborator

Deutsches Herzzentrum der Charité